Ligand Enters into OmniAb Platform License with xCella

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with its OmniAb Platform License with xCella Biosciences for human antibody discovery using transgenic rodents. 

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. xCellla is a protein engineering and drug discovery company.